SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, 400 056, India.
J Mater Sci Mater Med. 2021 Jul 31;32(8):88. doi: 10.1007/s10856-021-06558-y.
Atopic dermatitis (AD) and psoriasis are highly prevalent, complex, chronic inflammatory skin diseases that immensly affect the patient's quality of life. While there is no definitive cure for these conditions, suppressive medications aim at managing the symptoms of these diseases. The application of emollients accompanied by symptomatic anti-inflammatory therapy consisting of topical corticosteroids (TCS) is extensively employed for controlling the symptoms among general practitioners making this therapeutic class an indispensable pillar of dermatotherapeutics. The first TCS, hydrocortisone (HC) introduced in the early 1950s led to the development of different steroidal moieties of varying potencies by inducing chemical modifications to the basic steroid structure. The wide spectrum of the available range of formulations and potency provides flexibility to treat all patient groups, different phases of the diseases, and different anatomical sites. Conventional TCS therapy suffers from drawbacks such as low drug permeation and retention rate. Thus, novel nanoformulations have been developed to overcome these problems. This review provides an insight into the current state of nanocarrier-mediated topical delivery of corticosteroids monotherapy and combination therapy with special emphasis on targeting psoriasis and AD.
特应性皮炎（AD）和银屑病是高发、复杂、慢性炎症性皮肤病，极大地影响了患者的生活质量。虽然这些疾病没有明确的治愈方法，但抑制性药物旨在控制这些疾病的症状。在全科医生中，大量使用润肤剂和对症抗炎治疗（包括局部皮质类固醇（TCS））来控制症状，这使得该治疗类别成为皮肤病学不可或缺的支柱。20 世纪 50 年代早期引入的第一种 TCS——氢化可的松（HC）通过对基本类固醇结构进行化学修饰，导致了不同效力的不同甾体部分的发展。现有制剂和效力范围广泛，为治疗所有患者群体、疾病的不同阶段和不同解剖部位提供了灵活性。传统 TCS 治疗存在药物渗透和保留率低等缺点。因此，已经开发了新型纳米制剂来克服这些问题。本综述深入了解了目前纳米载体介导的皮质类固醇单药和联合治疗的局部递药情况，特别强调了针对银屑病和 AD 的靶向治疗。
